Breakthrough research shows that stem cell genes can be edited in living systems
New research led by Harvard scientist Amy Wagers has demonstrated that gene-editing machinery can be delivered straight to stem cells where they live, rather than in a dish. Published in Cell Reports, the findings have major implications for biotechnology research and the development of therapeutics for genetic diseases.
“If you want to change a genome to correct a disease-causing gene mutation, you have to change it in the relevant stem cells,” said Wagers, the Forst Family Professor of Stem Cell and Regenerative Biology. “If you don’t change the stem cells, whatever cells you do fix may eventually be replaced with diseased cells fairly quickly. If you do fix the stem cells, they will create healthy cells that can eventually replace the diseased cells.”
But fixing stem cells is harder than it sounds. The way it works now, stem cells have to be extracted, kept alive and healthy, genetically altered, then put back in the patient’s body. The process is disruptive for the cells, which may ultimately be rejected or fail to engraft back into the patient.
Each type of stem cell lives in its own “niche,” well-protected in hard-to-reach areas such as bone marrow. “When you take stem cells out of the body, you take them out of the very complex environment that nourishes and sustains them, and they kind of go into shock,” Wagers said. “Isolating cells changes them. Transplanting cells changes them. Making genetic changes without having to do that would preserve the regulatory interactions of the cells — that’s what we wanted to do.”
Transport by virus
Wagers’ group used an adeno-associated virus (AAV) that infects human (and mouse) cells—but does not cause disease—as a transport vehicle. Building on their earlier work in mice with Duchenne muscular dystrophy, Wagers and her colleagues created various AAV packages to deliver gene-editing cargo into several different types of skin, blood, and muscle stem and progenitor cells.
“This was a true collaboration between labs specializing in several different organs,” said Jill Goldstein, a postdoctoral fellow in the Wagers lab and co-first author of the study. “We set up experiments in our organs of interest, analyzed them, compared notes, and made adjustments in a kind of scientific assembly line. None of us could have done it alone — it takes a lot of hands, and the team approach made it really fun.”
To test whether their AAV complexes managed to deliver, the researchers used mice that act as so-called reporter systems via a “reporter” gene that is normally silenced but can be turned on by gene editing. When the reporter gene is activated, the cell turns bright, fluorescent red.
Up to 60 percent effective
The researchers observed that in skeletal muscle, up to 60 percent of the stem cells turned fluorescent red. In cells that give rise to different types of skin cells, up to 27 percent of the cells turned red. Up to 38 percent of the stem cells in bone marrow (which make blood) were changed. That might seem low, but blood turns over so quickly that in some cases even a single healthy stem cell may be sufficient to rescue a defect.
“So far, the concept of delivering healthy genes to stem cells using AAV hasn’t been practical because these cells divide so quickly in living systems — so the delivered genes will be diluted from the cells rapidly,” said Sharif Tabebordbar, an alumnus of Harvard’s Department of Stem Cell and Regenerative biology and now a postdoctoral fellow at the Broad Institute. “Our study demonstrates that we can permanently modify the genome of stem cells, and therefore their progenies, in their normal anatomical niche. There is a lot of potential to take this approach forward and develop more durable therapies for different forms of genetic diseases. That includes different forms of muscular dystrophy, where tissue regeneration is such an important factor.”
“We looked at the skin of these AAV-transduced mice from the Wagers lab, and were pleased to see that many dermal cells were successfully edited as well,” said Ya-Chieh Hsu, Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology. “Those included cells that give rise to dermal adipocytes, and cells that help regulate other stem cells in the skin. We’ve always needed a tool that lets us manipulate dermal cells in vivo rapidly — so for us, this is like a dream come true.”
‘Things might start to move very quickly’
Delivering a gene therapy directly into a living system has been a barrier for biotech companies trying to develop therapies for diseases like spinal muscular atrophy.
“This is a really important resource for the community for two reasons,” Wagers said. “First, it changes the way we can study stem cells in the body. The AAV approach lets researchers investigate the importance of different genes for stem cells in their native environment, much more quickly than ever before. Because the delivery system is so robust, it can also be used to target genes that affect many different tissues.
“Secondly, it’s an important step toward developing effective gene therapies. The approach we developed gets around all the problems you introduce by taking stem cells out of a body and allows you to correct a genome permanently. AAVs are already being used in the clinic for gene therapy, so things might start to move very quickly in this area.”
Learn more: Editing genes at the source
The Latest on: Gene therapy
[google_news title=”” keyword=”gene therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene therapy
- Experimental gene therapy shows promise for treating herpes infectionson May 14, 2024 at 1:09 am
Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much ...
- Great Ormond Street hoping to license gene therapy for ‘bubble baby’ syndromeon May 13, 2024 at 10:03 pm
Hospital to take unprecedented step after drug firm pulled out despite successful trial of treatment ...
- New gene therapy model offers hope for X-linked sideroblastic anemia treatmenton May 13, 2024 at 5:00 pm
Researchers at Children's Hospital of Philadelphia have pioneered a new gene therapy model that offers a potential breakthrough in treating X-linked sideroblastic anemia (XLSA), a rare congenital ...
- In a World First, Gene Therapy Restores Child’s Hearingon May 13, 2024 at 9:06 am
The development was made possible through an innovative gene therapy performed at Addenbrooke’s Hospital, Cambridge, Britain, making Opal the first person ever to benefit from the advanced treatment, ...
- Breakthrough Gene Therapy Enables Infant Born Deaf to Hearon May 12, 2024 at 5:00 pm
according to the results of a first-in-human gene therapy trial presented at the annual meeting of the American Society of Gene & Cell Therapy, held from May 7 to 11 in Baltimore. The gene therapy ...
- Gene therapy provision would make life-saving treatment more accessible and equitableon May 12, 2024 at 3:00 pm
A conference committee at the Minnesota Legislature will decide whether to include the coverage provision in the final version of the bill.
- Baby born deaf hears after unique gene therapyon May 12, 2024 at 9:33 am
Opal Sandy, now 18 months old, was completely deaf at birth due to a rare genetic condition called auditory neuropathy. But within four weeks of receiving a gene therapy infusion in her right ear as ...
- More children gain hearing as gene therapy for profound deafness advanceson May 10, 2024 at 3:08 pm
Enlarge / Opal Sandy (center), who was born completely deaf because of a rare genetic condition, can now hear unaided for the first time after receiving gene therapy at 11-months-old. She is shown ...
- Toddler born deaf can hear after gene therapy trial breakthrough her parents call "mind-blowing"on May 10, 2024 at 1:34 pm
The parents of a U.K. toddler say it's "absolutely mind-blowing" to see their daughter, enrolled in a gene therapy trial, hear for the first time.
- Gene Therapy Trial Restores Hearing in Baby Girlon May 10, 2024 at 10:30 am
A gene therapy trial at Cambridge University Hospitals in the UK has improved the hearing of an 18-month-old baby girl, born deaf due to auditory neuropathy.
via Bing News